Hologic logo, dark blue
Hologic logo, dark blue

APHL 2023

May 22-25, 2023
Sacramento, CA
SAFE Credit Union Convention Center

Visit Hologic Booth 401/403

Register
APHL-photo

We look forward to meeting our Public Health Laboratory Partners at APHL!

Technology session
Tuesday May 23rd,
7:00–7:30 am

Mycoplasma genitalium: the Southeastern States Prevalence Study & the Future of Testing Within Public Health


Join us for a panel discussion highlighting key findings from the study and dive into the future outlook of M. gen testing across Public Health. Panelists will share their experiences and discuss current challenges and benefits of generating data to support M. gen testing.

Sharon Massingale image

Susanne Crowe, MHA
Laboratory Director at the Florida Health Bureau of Public Health Laboratories

William A. Glover, II, Ph.D., D (ABMM), MT (ASCP)
Assistant Director, Infectious Diseases at the North Carolina State Laboratory of Public Health

Marie Claire Rowlinson, PhD, D (ABMM)
Chief, Bacterial Diseases at the Wadsworth Center, New York State Department of Health

Sharon Massingale, PhD, HCLD/CC (ABB)
Laboratory Director at the Alabama Department of Public Health, Bureau of Clinical Laboratories

Relevant Poster Presentation:

Development of Candida auris Surveillance RT-PCR Test in a Prison Hospital Setting

Filipe Cerqueira, Teresa York, Mary Ann DeMaet, Janak Patel, April McDougal, Natalie Williams-Bouyer, Ping Ren. University of Texas Medical Branch

Recorded sessions from past public health meetings

APHL 2022 Roundtable -- Emerging from COVID: What is the new normal for molecular testing?

AIDS Symposium Recordings Hema Srinivasan, MedAccess

AIDS Symposium Recordings Dr. Alan Staple, The Clinton Health Access Initiative

AIDS Symposium Recordings Dr. Alan Staple, The Clinton Health Access Initiative

Old Pathogens Meet New Testing Practices

Updates to STI and HIV testing routines

Read Lab Matters Article
Asian male health provider in lab coat in a lab setting.
Front view of Panther system with no background

This year in Sacramento, we would like to introduce you to our fully-automated Panther® system, the foundation of Panther® Scalable Solutions.

We would love to discuss in person how Panther® Scalable Solutions can help streamline your lab’s workflow and customize molecular diagnostic testing. With the Panther® system you can choose from a broad assay menu and a suite of instrument add-ons, providing an economical and scalable path to your laboratory’s growth.

Discover how Panther® Scalable Solutions can meet your needs in molecular diagnostic testing today and also prepare your lab for an unpredictable future by reducing complexities and decreasing turnaround times.

Explore Panther Scalable Solutions

20

Assays available

11

More in development

1

Scalable Platform

Lab technician's hand places a cartridge into a tray to be tested in a lab setting.

Unlock your lab's potential and learn more about Panther Fusion® Open Access™

Laboratory Developed Tests (LDTs) are an essential diagnostic tool for Public Health Laboratories.

Patients with certain medical conditions depend on these in-house developed tests when other options are not available. Save time and increase efficiency by consolidating your LDTs and IVD assays on the fully automated, sample-to-result, Panther Fusion system using the Open Access™ functionality.

Learn More

What’s in the way of Africawide molecular diagnostic roll out?

How are molecular diagnostics expanding access to diagnostic testing for viral diseases in low resource settings? Devex investigates.

Read Devex Story
Two African-American male lab technicians looking at a display monitor in a lab setting.

Public health labs are at the forefront of the battle to diagnose HIV & Hepatitis

Together we can improve care where it is needed most

No matter the size of your lab, you can support your clinicians with reliable, accurate results with the Aptima Virology assays.

The Aptima® HCV Quant Dx assay is standardized against the 2nd WHO International Standard for Hepatitis C Virus (NIBSC Code 96/798). Targeting, amplification, and detection are all conducted on the Panther system.

The Aptima HIV-1 Quant Dx assay is a dual-claim assay that can be used to confirm HIV-1 infection and measure viral load for optimal patient management.

Aptima® HIV-1 Quant Dx Assay

Aptima® HIV-1 Quant Dx Assay

Aptima® HCV Quant Dx Assay

Aptima® HCV Quant Dx Assay

Aptima® HBV Quant Assay

Aptima® HBV Quant Assay

The Hologic Global Access Initiative is a partnership with the Clinton Health Access Initiative, Inc. (CHAI) and MedAccess (backed by the UK government) to mitigate the burden of viral diseases in areas with high prevalence by providing greater access to testing using the Panther system.

Visit Hologic Booth 401/403 to discuss how Hologic is involved!

Photo of Aptima and Panther Fusion assays on table in a lab setting.

Visit Hologic Booth 401/403 and learn more about personalized respiratory testing

The Panther Fusion respiratory assays provide the flexibility to run patient-specific targets, allowing for personalized patient testing and better cost control in your lab.

  • The Panther Fusion Flu A/B/RSV assay - Qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus.1
  • The Panther Fusion AdV/hMPV/RV assay - Qualitative detection and differentiation of adenovirus, human metapneumovirus and rhinovirus.2
  • The Panther Fusion Paraflu assay - Qualitative detection and differentiation of parainfluenza virus 1-4.3
  • The Hologic® SARS-CoV-2 assays* - Qualitative detection of SARS-CoV-2 virus.4

Comparative analysis of four sample-to-result influenza A/B/RSV nucleic acid amplification assays using adult respiratory specimens.

Read More
Female lab technician removing rack of vials from Panther system in lab setting.
ONE Sample logo on white background

Laboratory Professionals Play an Essential Role in the Fight Against STIs

Mycoplasma genitalium (M. gen) is a highly prevalent sexually transmitted infection (STI). The CDC recommends M. gen testing for patients with recurring cervicitis and urethritis.5

The test you choose matters

The Aptima® Mycoplasma genitalium assay is a nucleic acid amplification test (NAAT) that enables efficient and reliable testing by detecting rRNA.

The sensitivity of RNA-based tests is needed for accurate diagnosis of M. gen. An RNA-based test accurately identified the 40% of patients missed by a DNA-based test.6

Learn More

Visit us at Hologic Booth 401/403 to expand your testing menu.

DNA-based tests can miss 40% of infections compared to rRNA-based tests.6

rRNA-based Aptima Mycoplasma genitalium assay provides up to 100% sensitivity.6

Assay Menu

Women's Health

CT/NG

Mycoplasma genitalium

Trichomonas vaginalis

Bacterial vaginosis

Candida vaginosis/Trichomonas vaginalis

HSV 1 & 2

HPV

HPV 16 18/45

Zika Virus*

GBS

M. gen macloide resistance†

Chlamydia trachomatis†

Neisseria gonorrhoeae†

Infectious Disease

HIV-1 Quant DX

HCV Quant DX

HBV Quant

CMV Quant

Flu A/B/RSV

Paraflu

AdV/hMPR/RV 

SARS-CoV-2*

SARs-CoV-2/Flu/A/B*

SARS-CoV-2Flu/A/B/RSV†

GI Bacterial†

GI Extended Bacterial†

GI Viral†

GI Parasite†

EBV†

BKV†

C. Difficule†

References:
1. Panther Fusion Flu A/B/RSV assay. US package insert AW-16832-001. Hologic, Inc.; 2019. 2. Panther Fusion AdV/hMPV/RV assay. US package insert AW-16834-001. Hologic, Inc.; 2019. 3. Panther Fusion Paraflu assay. US package insert AW-16833-001 Hologic, Inc.; 2019. 4. Panther Fusion SARS-CoV-2 assay. US package insert AW-21159-001. Hologic, Inc.; 2022. 5. Workowski KA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1. 6. Le Roy C, Pereyre S, Hénin N, Bébéar C. French prospective clinical evaluation of the Aptima Mycoplasma genitalium CE-IVD assay and macrolide resistance detection using three distinct assays. J Clin Microbiol. 2017;55(11):3194-3200.
 
Disclaimer: 
*The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/ Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A, Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/ or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. 

†In development and not for sale.